3-[(2-乙氧基苯氧基)甲基]哌啶 | 104778-54-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-[(2-乙氧基苯氧基)甲基]哌啶
• 英文名称: 3-<(2-ethoxyphenoxy)methyl>piperidine
• 英文别名: 3-[(2-Ethoxyphenoxy)methyl]piperidine
• CAS: 104778-54-3
• 化学式: C₁₄H₂₁NO₂
• mdl: MFCD01700574
• 分子量: 235.326
• InChiKey: UQUOUCIJKBLYMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090

反应信息

• 作为产物：
  描述：

  烟酸乙酯 在 palladium on activated charcoal 盐酸 、 氯化亚砜 、 氢气 、 sodium 、 potassium carbonate 作用下， 以 乙醇 、 氯仿 、 丙酮 为溶剂， 反应 66.5h， 生成 3-[(2-乙氧基苯氧基)甲基]哌啶
  参考文献：
  名称：

  3-[（2-乙氧基苯氧基）甲基]哌啶衍生物。合成和抗抑郁活性。

  摘要：

  合成了3-[（2-乙氧基苯氧基）甲基]哌啶衍生物3-5，并通过利血平相互作用试验筛选了潜在的抗抑郁药，并评估了猪脑突触体组分中生物胺的再摄取抑制作用。此外，还评估了它们的抗惊厥活性（通过戊二唑对映体测试）和近似的急性毒性。体内和体外试验表明，化合物3和5具有与抗抑郁药维洛嗪相当的生物活性。

  DOI：

  10.1021/jm00384a040

文献信息

• METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF
  申请人：Liang Likan

  公开号：US20110251198A1

  公开（公告）日：2011-10-13

  Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantially pure API of viloxazine HCl while avoiding undesirable impurities. The methods further provide for separating, identifying, and characterizing novel polymorphs of viloxazine. Further provided are methods for synthesis and identification and characterization of novel intermediates of viloxazine, as well as for some important metabolites and precursors of metabolites of viloxazine.

  这里提供了制备维洛西嗪及其各种盐的方法，以及维洛西嗪相关化合物，如新型中间反应产物和其多晶形式。具体而言，这些方法提供了维洛西嗪盐酸盐的基本纯净API，同时避免了不良杂质。这些方法进一步提供了分离、鉴定和表征维洛西嗪新型多晶形式的方法。此外，还提供了维洛西嗪新中间体的合成、鉴定和表征方法，以及一些重要代谢产物和代谢产物前体的合成方法。
• [EN] AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS<br/>[FR] DERIVES AMIDIQUES COMME ANTAGONISTES DU RECEPTEUR NMDA
  申请人：RICHTER GEDEON VEGYESZET

  公开号：WO2002034718A1

  公开（公告）日：2002-05-02

  The invention relates to new NR2B selective NMDA receptor antagonist carboxylic acid amide derivatives of formula (I) as well as the recemates, optical antipodes and the salts thereof formed with acids and bases. Fruthermore objets of the present invention are the pharmaceutical compositions containing compounds of formula (I) or the salts thereof as active ingredients, as well as the synthesis of compounds of formula (I), and the chemical and pharmaceutical manufacture of medicaments containing these compounds, as well as the method of treatments with these compounds, which means administering to a mammal to be treated - including human - effective amount/amounts of compounds of formula (I) of the present invention as such or as medicament. The new carboxylic acid amide derivatives of formula (I) of the present invention are highly effective and selective antagonists of NMDA receptor, and moreover most of the compounds are selective antagonist of NR2B subtype of NMDA receptor.

  本发明涉及公式（I）的新型NR2B选择性NMDA受体拮抗剂羧酸酰胺衍生物，以及与酸和碱形成的外消旋体，光学对映体和其盐。此外，本发明的目标是含有公式（I）化合物或其盐作为活性成分的制药组合物，以及公式（I）化合物的合成，以及含有这些化合物的药物的化学和制药制造，以及使用这些化合物的治疗方法，即向待治疗的哺乳动物（包括人类）施用本发明的化合物的有效量/量，作为药物或单独使用。本发明的新型羧酸酰胺衍生物的公式（I）是高效和选择性的NMDA受体拮抗剂，而且大多数化合物是NMDA受体NR2B亚型的选择性拮抗剂。
• Piperidine Derivatives
  申请人：Caprathe Bradley W.

  公开号：US20100120858A1

  公开（公告）日：2010-05-13

  The invention relates to compounds of Formula (I) and pharmaceutically acceptable acid addition salts thereof, wherein *, X 1 , X 2 , R 5A , R 5B , R 6 , R 7 , and R 8 are as defined in the specification; pharmaceutical compositions; therapeutic combinations; and methods of treating diseases and disorders.

  本发明涉及式（I）化合物及其药学上可接受的酸盐，其中*、X1、X2、R5A、R5B、R6、R7和R8如规范中所定义；药物组合物；治疗疾病和疾病的方法。
• Phenoxymethyl piperidine derivatives being sodium channle blockers
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0869119A1

  公开（公告）日：1998-10-07

  The present invention relates to phenoxymethyl piperidine derivatives, and pharmaceutically acceptable salts and N-oxides thereof, which are sodium channel blockers, and thus exhibit useful pharmacological properties, including utility for the treatment of neuropathic pain conditions. represented by formula I: where: R1 is hydrogen, (C1-4)alkyl, -(CH2)mcycloalkyl, -(CH2)mNR7R8, or -(CH2)mNR7SO2R9; m is 1 to 3; R7 and R8 are independently hydrogen or (C1-4)alkyl; and R9 is (C1-4)alkyl; R2,R3,R5, and R6 are independently hydrogen, (C1-4)alkyl, or halogen; R4 is hydrogen, (C1-4)alkyl, hydroxy, alkyloxy, fluoroalkyloxy, halogen, or phenyl or mono- or di-substituted phenyl, the substituents selected from alkyloxy, amino, nitro or acetylamino; provided that when R1 is hydrogen at least two of R2,R3,R4,R5, and R6 are other than hydrogen; and further provided that when R1 is methyl and R2,R3,R5 and R6 are hydrogen, R4 is other than fluoro; or a pharmaceutically acceptable salt or N-oxide thereof, as an individual isomer or as a racemic or non-racemic mixture of isomers.

  本发明涉及苯氧基甲基哌啶衍生物及其药学上可接受的盐和 N-氧化物，它们是钠通道阻滞剂，因此具有有用的药理特性，包括用于治疗神经性疼痛病症。 由式 I 表示： 其中 R1 是氢、(C1-4)烷基、-(CH2)m 环烷基、-(CH2)mNR7R8 或-(CH2)mNR7SO2R9； m 为 1 至 3； R7 和 R8 独立地为氢或 (C1-4)烷基；以及 R9 是 (C1-4)烷基； R2、R3、R5 和 R6 独立地是氢、(C1-4)烷基或卤素； R4 是氢、(C1-4)烷基、羟基、烷氧基、氟烷氧基、卤素或苯基或单取代或二取代苯基，取代基选自烷氧基、氨基、硝基或乙酰氨基； 当 R1 为氢时，R2、R3、R4、R5 和 R6 中至少有两个不是氢；当 R1 为甲基，R2、R3、R5 和 R6 为氢时，R4 不是氟； 或其药学上可接受的盐或 N-氧化物，作为单个异构体或作为异构体的外消旋或非外消旋混合物。
• BALSAMO A.; GIORGI I.; LAPUCCI A.; LUCACCHINI A.; MACCHIA B; MACCHIA F.; +, J. MED. CHEM., 30,(1987) N 1, 222-225
  作者：BALSAMO A.、 GIORGI I.、 LAPUCCI A.、 LUCACCHINI A.、 MACCHIA B、 MACCHIA F.、 +

  DOI：——

  日期：——